Replimune Group (REPL)
NASDAQ:REPL
Want to see REPL full AI Analyst Report?
REPL Stock Chart & Stats
$2.17
$0.17(1.56%)
At close: 4:00 PM EST
$2.17
$0.17(1.56%)
Day’s Range― - ―
52-Week Range$1.50 - $13.24
Previous CloseN/A
Volume95.41K
Average Volume (3M)7.49M
Market Cap
$739.85M
Enterprise Value$678.38M
Total Cash (Recent Filing)$269.14M
Total Debt (Recent Filing)$76.35M
Price to Earnings (P/E)―
Beta0.26
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.58
Shares Outstanding82,572,620
10 Day Avg. Volume4,203,493
30 Day Avg. Volume7,489,601
Financial Highlights & Ratios
PEG Ratio0.61
Price to Book (P/B)1.89
Price to Sales (P/S)0.00
P/FCF Ratio-3.95
Enterprise Value/Market Cap0.92
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-799.98
Enterprise Value/Ebitda-2.18
Forecast
1Y Price Target
$4.20Price Target Upside93.55% Upside
Rating ConsensusHold
Number of Analyst Covering8
EPS Forecast (FY)-1.77
Revenue Forecast (FY)$16.78M
Bulls Say, Bears Say
Bulls Say
Late-stage Pipeline & Regulatory ProgressRegulatory milestones and late-stage studies materially reduce binary clinical risk and improve strategic optionality. BLA acceptance and a set PDUFA date indicate meaningful near-term regulatory clarity, enabling focused commercial preparation and partnership or financing strategies that alter the company’s long-term funding and execution path.
Extended Funding Runway Via Hercules AmendmentThe loan amendment materially extends financial flexibility by deferring amortization and providing immediate and milestone-linked funding. This structural change reduces near-term refinancing pressure, supports sustained R&D and commercial launch prep, and lowers the risk that program timelines are disrupted by short-term liquidity needs.
Modest Debt LeverageRelatively low debt levels limit fixed financial obligations and preserve borrowing capacity, giving management more tactical room to fund trials or opportunistic partnerships. Modest leverage reduces insolvency risk versus highly levered peers and supports the ability to pursue non-dilutive financing or structured milestone funding.
Bears Say
Zero Revenue And Widening LossesAs a clinical-stage biotech without product sales, the company records no revenue while operating losses have materially widened. Sustained negative profitability means ongoing reliance on external capital; absent regulatory approval or partnerships, continued losses will pressure liquidity and shareholder dilution over the medium term.
High, Rising Cash BurnLarge negative operating and free cash flows indicate that losses translate into real cash outflows, not just non-cash accounting items. Persistent, rising burn depletes available resources, forces frequent capital raises, and elevates execution risk for trials and commercialization unless milestone-linked funding or successful approval changes the cash profile.
Eroded Equity CushionA sharp decline in shareholders' equity weakens the capital buffer against setbacks and increases sensitivity to adverse events. Reduced equity limits non-dilutive funding options and raises the probability of dilutive financing or restrictive deal terms, constraining long-term strategic flexibility and increasing stakeholder financing risk.
Replimune Group News
REPL FAQ
What was Replimune Group’s price range in the past 12 months?
Replimune Group lowest stock price was $1.50 and its highest was $13.24 in the past 12 months.
What is Replimune Group’s market cap?
Replimune Group’s market cap is $739.85M.
When is Replimune Group’s upcoming earnings report date?
Replimune Group’s upcoming earnings report date is Aug 06, 2026 which is in 50 days.
How were Replimune Group’s earnings last quarter?
Currently, no data Available
Is Replimune Group overvalued?
According to Wall Street analysts Replimune Group’s price is currently Undervalued.
Does Replimune Group pay dividends?
Replimune Group does not currently pay dividends.
What is Replimune Group’s EPS estimate?
Replimune Group’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Replimune Group have?
Replimune Group has 82,572,620 shares outstanding.
What happened to Replimune Group’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Replimune Group?
Currently, no hedge funds are holding shares in REPL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Replimune Group Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$4.20 (93.55% Upside)
$4.20 (93.55% Upside)
Blogger Sentiment
Bullish
REPL Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 132.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $474.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.3%
Last 30 Days ▲ 9.5%
Last 30 Days ▲ 9.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-10.68%
12-Months-Change
Fundamentals
Return on Equity
-102.69%
Trailing 12-Months
Asset Growth
-44.74%
Trailing 12-Months
Company Description
Replimune Group
Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1. This candidate is presently in Phase I/II clinical trials for a range of solid tumors and has also progressed to Phase II trials specifically for patients with cutaneous squamous cell carcinoma. Replimune is additionally developing RP2, an anti-CTLA-4 antibody-like protein, which is undergoing Phase I clinical assessment. Its purpose is to counteract the immune system's suppression often mediated by CTLA-4. Furthermore, RP3, also in Phase I clinical trials, is engineered to express immune-activating proteins that stimulate T cells. Established in 2015, Replimune Group, Inc. maintains its corporate headquarters in Woburn, Massachusetts.
REPL Stock 12 Month Forecast
Average Price Target
$4.20
▲(93.55% Upside)
Technical Analysis
Anavex Life Sciences
―
Arcus Biosciences
―
Oric Pharmaceuticals
―
Nurix Therapeutics
―
Sana Biotechnology
―
Ownership Overview
3.54% Insiders
17.62% Mutual Funds
49.62% Other Institutional Investors
16.26% Public Companies and
Individual Investors